 "Piramal Pharma ends at Rs 192 on debut, valued at Rs 22,882 cr at close")
Shares of Piramal Pharma closed at Rs 192 on Wednesday during their listing debut.
The company, which got listed separately following its demerger from Piramal Enterprises, was valued at Rs 22,882 crore at last close.
The company, which got listed separately following its demerger from Piramal Enterprises, was valued at Rs 22,882 crore at last close.
In FY22, the contract development and manufacturing (CDMO) vertical accounted for 59 per cent of its sales, complex hospital generics (CHG), 30 per cent and India consumer products business, 11 per cent.
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock.
“Using sum of the parts (SOTP), we value the CDMO business, CHG, and the ICH business based on 16x, 12x, and 18x FY24E EV/EBITDA respectively. We value Allergan JV (49 per cent stake) based on 18x FY24E PE,” it says.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%